Kalaris Therapeutics (KLRS) Price & Analysis

Compare

358 Followers

KLRS Stock Chart & Stats

$4.63

Market closed

$4.63

Day’s Range― - ―

52-Week Range$2.14 - $24.15

Previous CloseN/A

VolumeN/A

Average Volume (3M)223.02K

Market Cap

$77.50M

Enterprise Value-$38.49M

Total Cash (Recent Filing)$100.97M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.18

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-11.75

Shares Outstanding18,702,417

10 Day Avg. Volume268,364

30 Day Avg. Volume223,022

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.50

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda4.40

Forecast

1Y Price Target

$15.33

Price Target Upside231.10% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentThe initiation of a Phase Ib/II study of TH103 in patients with neovascular age-related macular degeneration represents a key advance in the clinical development program.

LeadershipKalaris recently expanded its leadership team with the hiring of an SVP of clinical, Kristine Curtiss, who brings over 25 years of clinical research operations experience in ophthalmology-focused biotech companies.

Market PotentialTH103 has the potential to offer better outcomes and longer treatment intervals than current anti-VEGF therapies for the treatment of retinal vascular diseases, which represents a roughly $15 billion market globally.

Bears Say

Preclinical DataThe preclinical data for the company's anti-VEGF, TH103, are not sufficient evidence to provide what the differentiation would be compared to standard of care in retinal diseases.

Trial DesignThe trial could have included a comparator arm which would have provided a much clearer assessment of TH103's clinical benefit.

Kalaris Therapeutics News

Optimistic Buy Rating for Kalaris Therapeutics: Advancements in TH103 for nAMD

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on KLRS stock, giving a Buy rating...

1M ago

KLRS

Kalaris Therapeutics now enrolling Phase 1b/2 MAD study of TH103

Kalaris Therapeutics (KLRS) announced that it is now enrolling a Phase 1b/2 multiple ascending dose, MAD, study of...

1M ago

KLRS

Kalaris Therapeutics initiated with a Strong Buy at Raymond James

Raymond James analyst Christopher Raymond initiated coverage of Kalaris Therapeutics (KLRS) with a Strong Buy rating and $23...

2M ago

KLRS

Kalaris Therapeutics Reports Q2 2025 Financial Results

Kalaris Therapeutics, Inc. ( ($KLRS) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

KLRS

Kalaris Therapeutics Elects New Directors at Annual Meeting

Kalaris Therapeutics ( ($KLRS) ) just unveiled an announcement. At the 2025 Annual Meeting of Stockholders held on...

2M ago

KLRS

Kalaris Therapeutics reports Q2 EPS (61c), consensus (52c)

“We continued to enroll treatment-naive nAMD patients in our open-label Phase 1 clinical trial of TH103 in the...

2M ago

KLRS

Kalaris Therapeutics assumed with a Neutral at Piper Sandler

Piper Sandler analyst Biren Amin assumed coverage of Kalaris Therapeutics (KLRS) with a Neutral rating and $3 price...

3M ago

KLRS

Cautious Hold on Kalaris Therapeutics: Awaiting Key Data on TH103’s Potential in Wet AMD

Biren Amin, an analyst from Piper Sandler, maintained the Hold rating on Kalaris Therapeutics. The associated price target...

3M ago

KLRS

Three new option listings and ten option delistings on July 21st

New option listings for July 21st include Cohen Circle Acquisition Corp. I – Class A Ordinary Shares (CCIR),...

3M ago

HES

Kalaris Therapeutics Adjusts Annual Meeting Schedule

Kalaris Therapeutics ( ($KLRS) ) has provided an announcement. Kalaris Therapeutics, Inc. has announced that its 2025 annual...

4M ago

KLRS

Positive Outlook on Kalaris Therapeutics: Promising Phase 1 Trial and Strong Financial Position Justify Buy Rating

Analyst Marc Goodman of Leerink Partners reiterated a Buy rating on Kalaris Therapeutics (KLRS – Research Report), retaining...

5M ago

KLRS

Kalaris Therapeutics Reports Q1 2025 Financials and Progress

Kalaris Therapeutics, Inc. ( ($KLRS) ) has released its Q1 earnings. Here is a breakdown of the information...

5M ago

KLRS

Buy Rating for Kalaris Therapeutics: Promising TH103 Development and Strong Financial Position

Lachlan Hanbury Brown, an analyst from William Blair, has initiated a new Buy rating on Kalaris Therapeutics (KLRS)....

5M ago

KLRS

Kalaris Therapeutics reports Q1 EPS ($2.52) vs ($2.60) last year

“We are excited by our progress in 2025,” said Andrew Oxtoby, Chief Executive Officer of Kalaris. “We recently...

5M ago

KLRS

KLRS FAQ

What was Kalaris Therapeutics’s price range in the past 12 months?

Kalaris Therapeutics lowest stock price was $2.14 and its highest was $24.15 in the past 12 months.

What is Kalaris Therapeutics’s market cap?

Kalaris Therapeutics’s market cap is $77.50M.

When is Kalaris Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Kalaris Therapeutics’s earnings last quarter?

Kalaris Therapeutics released its earnings results on May 14, 2025. The company reported -$2.52 earnings per share for the quarter, missing the consensus estimate of -$0.775 by -$1.745.

Is Kalaris Therapeutics overvalued?

According to Wall Street analysts Kalaris Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kalaris Therapeutics pay dividends?

Kalaris Therapeutics does not currently pay dividends.

What is Kalaris Therapeutics’s EPS estimate?

Kalaris Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kalaris Therapeutics have?

Kalaris Therapeutics has 18,702,417 shares outstanding.

What happened to Kalaris Therapeutics’s price movement after its last earnings report?

Kalaris Therapeutics reported an EPS of -$2.52 in its last earnings report, missing expectations of -$0.775. Following the earnings report the stock price went down -8.434%.

Which hedge fund is a major shareholder of Kalaris Therapeutics?

Currently, no hedge funds are holding shares in KLRS

Kalaris Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-50.68%

Trailing 12-Months

Asset Growth

-29.12%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kalaris Therapeutics

AlloVir, Inc. (ALVR) is a biotechnology company focused on developing allogeneic, off-the-shelf virus-specific T cell therapies designed to combat and prevent viral infections in immunocompromised patients. Operating in the healthcare and life sciences sector, AlloVir's core products include investigational therapies for treating viral infections such as cytomegalovirus, adenovirus, and BK virus, primarily targeting patients undergoing hematopoietic stem cell transplantation and other vulnerable populations.

Kalaris Therapeutics (KLRS) Earnings & Revenues

Historic Earnings Reports

KLRS Stock 12 Month Forecast

Average Price Target

$15.33

▲(231.10% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","46":"$46","12.25":"$12.25","23.5":"$23.5","34.75":"$34.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,12.25,23.5,34.75,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4,5.461538461538462,6.923076923076923,8.384615384615383,9.846153846153847,11.307692307692307,12.769230769230768,14.23076923076923,15.692307692307692,17.153846153846153,18.615384615384613,20.076923076923077,21.538461538461537,{"y":23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4,4.871538461538462,5.743076923076924,6.614615384615385,7.486153846153846,8.357692307692307,9.22923076923077,10.100769230769231,10.972307692307693,11.843846153846155,12.715384615384616,13.586923076923078,14.458461538461538,{"y":15.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4,3.923076923076923,3.8461538461538463,3.769230769230769,3.6923076923076925,3.6153846153846154,3.5384615384615383,3.4615384615384617,3.3846153846153846,3.3076923076923075,3.230769230769231,3.1538461538461537,3.0769230769230766,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.31,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.83,"date":1704067200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1709251200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.63,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":21.93,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >